GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicure Inc (OTCPK:MCUJF) » Definitions » EV-to-FCF

MCUJF (Medicure) EV-to-FCF : -14.43 (As of Dec. 13, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Medicure EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medicure's Enterprise Value is $4.42 Mil. Medicure's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.31 Mil. Therefore, Medicure's EV-to-FCF for today is -14.43.

The historical rank and industry rank for Medicure's EV-to-FCF or its related term are showing as below:

MCUJF' s EV-to-FCF Range Over the Past 10 Years
Min: -1421.18   Med: 3.25   Max: 16346.47
Current: -14.77

During the past 13 years, the highest EV-to-FCF of Medicure was 16346.47. The lowest was -1421.18. And the median was 3.25.

MCUJF's EV-to-FCF is ranked worse than
100% of 551 companies
in the Drug Manufacturers industry
Industry Median: 25.85 vs MCUJF: -14.77

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), Medicure's stock price is $0.70. Medicure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.144. Therefore, Medicure's PE Ratio (TTM) for today is At Loss.


Medicure EV-to-FCF Historical Data

The historical data trend for Medicure's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicure EV-to-FCF Chart

Medicure Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.25 -4.88 2.18 4.18 4.86

Medicure Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.03 4.86 4.43 9.43 -15.51

Competitive Comparison of Medicure's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicure's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicure's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Medicure's EV-to-FCF falls into.



Medicure EV-to-FCF Calculation

Medicure's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4.417/-0.306
=-14.43

Medicure's current Enterprise Value is $4.42 Mil.
Medicure's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicure  (OTCPK:MCUJF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Medicure's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.70/-0.144
=At Loss

Medicure's share price for today is $0.70.
Medicure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.144.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Medicure EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Medicure's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicure Business Description

Traded in Other Exchanges
Address
2 - 1250 Waverley Street, Winnipeg, MB, CAN, R3T 6C6
Medicure Inc is a biopharmaceutical company. It is involved in the research, clinical development, and commercialization of human therapeutics for the United States hospital market. Further, it also operates a specialty pharmacy in the United States of America. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.